Molecular Partners Ag Stock Market Value
| MLLCF Stock | USD 3.50 0.55 13.58% |
| Symbol | Molecular |
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 11/26/2025 |
| 12/26/2025 |
If you would invest 0.00 in Molecular Partners on November 26, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 30 days. Molecular Partners is related to or competes with Innate Pharma, Brii Biosciences, Scancell Holdings, JW (Cayman), NervGen Pharma, Ascend Wellness, and Santhera Pharmaceuticals. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 28.86 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | 0.0163 | |||
| Jensen Alpha | 0.0474 | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.07) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Partners' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Partners Backtested Returns
At this point, Molecular Partners is relatively risky. Molecular Partners has Sharpe Ratio of 0.013, which conveys that the firm had a 0.013 % return per unit of risk over the last 3 months. We have found nineteen technical indicators for Molecular Partners, which you can use to evaluate the volatility of the firm. Please verify Molecular Partners' Mean Deviation of 0.5844, risk adjusted performance of 0.0163, and Standard Deviation of 2.6 to check out if the risk estimate we provide is consistent with the expected return of 0.0348%. Molecular Partners has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Molecular Partners are expected to decrease at a much lower rate. During the bear market, Molecular Partners is likely to outperform the market. Molecular Partners right now secures a risk of 2.67%. Please verify Molecular Partners AG total risk alpha, as well as the relationship between the daily balance of power and day typical price , to decide if Molecular Partners AG will be following its current price movements.
Auto-correlation | -0.82 |
Excellent reverse predictability
Molecular Partners AG has excellent reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 26th of November 2025 to 11th of December 2025 and 11th of December 2025 to 26th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.82 indicates that around 82.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.82 | |
| Spearman Rank Test | -0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Molecular Partners lagged returns against current returns
Autocorrelation, which is Molecular Partners pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Molecular Partners' pink sheet expected returns. We can calculate the autocorrelation of Molecular Partners returns to help us make a trade decision. For example, suppose you find that Molecular Partners has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Molecular Partners regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Molecular Partners pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Molecular Partners pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Molecular Partners pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Molecular Partners Lagged Returns
When evaluating Molecular Partners' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Molecular Partners pink sheet have on its future price. Molecular Partners autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Molecular Partners autocorrelation shows the relationship between Molecular Partners pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Molecular Partners AG.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Molecular Partners Correlation, Molecular Partners Volatility and Molecular Partners Alpha and Beta module to complement your research on Molecular Partners. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Molecular Partners technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.